BioMarin Pharmaceutical Q3 2026 Earnings Date & Estimates

BioMarin Pharmaceutical (NASDAQ:BMRN) is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI. The company also markets Roctavian, a gene therapy for certain adults with severe hemophilia A.

Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets. Its products are generally distributed through specialized healthcare and reimbursement channels because of the complex nature of the diseases they address. Alexander Hardy serves as the company’s chief executive officer.